Proton beam therapy for hepatocellular carcinoma with bile duct invasion

BMC Gastroenterology

Research

Naoyuki Hasegawa¹  Emiko Seo¹  Kazunori Ishige²  Kuniaki Fukuda²  Hikaru Niitsu³  Toshiyuki Okumura³  Motohiro Murakami³  Takashi Saito³  Yuta Sekino³  Haruko Numajiri³  Takashi Iizumi³  Keiichiro Baba³  Mizuki Takahashi³  Hideyuki Sakurai³  Masashi Mizumoto³  Kei Nakai³  Hirokazu Makishima³  Yoshiko Oshiro⁴  Daichi Takizawa⁵  Hiroaki Takahashi⁶ 

[1]Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

[2]Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

[3]Department of Gastroenterology, Kasumigaura Medical Center, Ibaraki, Japan

[4]Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, 305-8576, Tsukuba, Ibaraki, Japan

[5]Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, 305-8576, Tsukuba, Ibaraki, Japan

[6]Department of Radiation Oncology, Tsukuba Medical Center Hospital, Tsukuba, Japan

[7]Department of Radiation Oncology, Hitachi General Hospital, Tsukuba, Japan

[8]Department of Radiology, Mayo Clinic, Rochester, USA

关键词: Bile duct invasion;    Bile duct tumor thrombosis;    Hepatocellular carcinoma;    Proton beam therapy;    Radiation therapy;   

DOI  :  10.1186/s12876-023-02897-y

 received in 2023-04-07, accepted in 2023-07-20,  发布年份 2023

来源: Springer

【 摘 要 】

AimHepatocellular carcinoma (HCC) with bile duct invasion (BDI) (BDIHCC) has a poor prognosis. Moreover, due to the paucity of reports, there is no consensus regarding optimal management of this clinical condition yet. The aim of this study was to clarify the efficacy and safety of proton beam therapy (PBT) for BDIHCC.MethodsBetween 2009 and 2018, 15 patients with BDIHCC underwent PBT at our institution. The overall survival (OS), local control (LC), and progression-free survival (PFS) curves were constructed using the Kaplan-Meier method. Toxicities were assessed using the Common Terminology Criteria of Adverse Events version 4.0.ResultsThe median follow-up time was 23.4 months (range, 7.9–54.3). The median age was 71 years (range, 58–90 years). Many patients were Child A (n = 8, 53.3%) and most had solitary tumors (n = 11, 73.3%). Additionally, most patients had central type BDI (n = 11, 73%). The median tumor size was 4.0 cm (range, 1.5–8.0 cm). The 1-, 2-, and 3-year OS rates were 80.0%, 58.7% and 40.2%, respectively, and the corresponding LC and PFS rates were 93.3%, 93.3%, and 74.7% and 72.7%, 9.7%, and 0.0%, respectively. Acute grade 1/2 dermatitis (n = 7, 46.7%), and grades 2 (n = 1, 6.7%) and 3 (n = 1, 6.7%) cholangitis were observed. Late toxicities such as grade 3 gastric hemorrhage and pleural effusion were observed. No toxicities of grade 4 or higher were observed.ConclusionsPBT was feasible with tolerable toxicities for the treatment of BDIHCC.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 6

Fig. 3

Fig. 3

Fig. 2